BioMarin Pharmaceutical Inc. announced that its enzyme-replacement therapy, PALYNZIQ, achieved a 49.7% reduction in mean blood phenylalanine levels among adolescents with phenylketonuria in a Phase-3 study, marking a significant milestone for the co…

BioMarin Pharmaceutical Inc. exceeded market expectations in Q2 2025, reporting a revenue of $825 million and raising its full-year guidance to $3.125 billion.

BioMarin Pharmaceutical Inc. has acquired Inozyme Pharma, expanding its enzyme therapy portfolio and positioning itself as a frontrunner in addressing rare diseases.